Announced Fri, 31 Jul · 17:20 IST
Q1 FY27: Revenue Rs 207 cr, PAT Rs 21 cr; CMD re-appointed, Rs 50 cr loan to subsidiary
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹374.50
prior close
₹375.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.7-2.1-2.0-2.9-2.9-4.5+1.2+0.4-0.1-5.5-0.1——
Up moveDown movePending
AI summary
SMS Pharmaceuticals reported Q1 FY27 standalone revenue of Rs 206.96 cr versus Rs 196.05 cr YoY, up 5.6 percent. PAT rose about 16 percent to Rs 21.13 cr from Rs 18.21 cr. EPS at Rs 2.26 versus Rs 2.05. Board approved an unsecured loan of up to Rs 50 cr to subsidiary SMS Peptides. Re-appointed CMD Ramesh Babu Potluri for 5 years from Oct 2026. AGM on Sept 23, 2026; record date Sept 16 for dividend. Auditor issued un-modified review report.
Likely market impact
Steady Q1 with mid-teens PAT growth. Subsidiary funding and CMD continuity signal stability. Watch Sept 16 record date for dividend.